MMAEX Ligands for Full and Empty AAV Capsid Separation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The inefficient purification of adeno-associated virus (AAV) capsids, particularly the separation of full and empty capsids, is a significant challenge due to their similar size and subtle differences in charge and hydrophobicity, leading to reduced therapeutic efficacy and immune responses.

Innovation Solution

Development of a multimodal anion exchange (MMAEX) ligand grafted onto membrane substrates, combining hydrophobic and anionic units, to selectively separate full and empty capsids through optimized chromatographic conditions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If gradient centrifugation is used to purify full viral capsids, then purification effectiveness is improved, but scalability and practicality deteriorate

Engineering Contradiction:
Improvepurification effectivenessVSAvoidscalability
Core Design Contradiction:
Manufacturing precisionVSProductivity

Solution Approach 1:

The patent replaces the mechanical centrifugation system with a chromatographic system using immobilized ligands. Instead of using centrifugal force to separate capsids based on density, the invention uses chemical interactions between ligands (such as polyethyleneimine, chitosan, or other cationic polymers) and the negatively charged surface of viral capsids to achieve separation. This substitution enables scalable purification through column chromatography while maintaining high purification effectiveness.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent exploits differences in surface charge parameters between full and empty capsids to achieve separation. By adjusting pH, ionic strength, and ligand density, the method optimizes binding conditions to selectively retain full capsids while allowing empty capsids to pass through. This parameter-based approach enables scalable purification without requiring complex centrifugation equipment.

Inventive Principle:
Principle #35Parameter changes

2Device complexity

If conventional purification methods are used, then process simplicity is maintained, but separation precision of full and empty capsids deteriorates

Engineering Contradiction:
Improveprocess simplicityVSAvoidseparation precision
Core Design Contradiction:
Device complexityVSManufacturing precision

Solution Approach 1:

The patent uses composite ligand systems combining multiple functional groups (e.g., cationic polymers with hydrophobic moieties, or combinations of different charged groups) to enhance separation precision. These composite materials provide multiple interaction modes with the capsid surface, improving the ability to distinguish between full and empty capsids while maintaining a relatively simple chromatographic process.

Inventive Principle:
Principle #40Composite materials

Solution Approach 2:

The patent modifies specific regions of the purification medium with targeted ligands that have enhanced affinity for full capsids. By creating localized zones of high binding capacity on the chromatographic support, the method achieves superior separation precision without complicating the overall process flow.

Inventive Principle:
Principle #3Local quality

3Productivity

If empty capsids are not removed, then production yield is maximized, but therapeutic effectiveness deteriorates and immune responses increase

Engineering Contradiction:
Improveproduction yieldVSAvoidtherapeutic effectiveness
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The patent implements empty capsid removal as a preliminary step before final product formulation. By using ligand-based chromatography to selectively capture full capsids and allow empty capsids to be washed away, the method ensures high therapeutic effectiveness while maintaining high recovery yields. This preliminary separation step is integrated into the purification workflow to prevent immune responses and enhance treatment efficacy.

Inventive Principle:
Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Achieves high recovery and purity of full capsids, up to 88% with a loading density of 1.3×1014 capsids/mL, while maintaining infectivity and reducing immune response risks.

Implementation Method 1

the ligand includes a hydrophobic unit and an anionic unit

Methodology Applied
Scientific EffectHydrophobic interaction: Hydrophobe

Implementation Method 2

multimodal anion exchange (MMAEX) ligand

Methodology Applied
Scientific EffectIon exchange: Ion Exchange

Data Source

PatentUS20250382326A1Multimodal anion exchange ligands for purification of viral particles and nucleic acids
Publication Date: 2025.12.18 THE BOARD OF TRUSTEES OF THE UNIV OF ARKANSAS
  • US20250382326A1 patent drawing
  • US20250382326A1 patent drawing
  • US20250382326A1 patent drawing

AI summary

A method and surface for separating materials are disclosed. The method includes associating the materials with a surface having a ligand. The ligand includes a hydrophobic unit and an anionic unit. The method further includes forming a material-ligand complex, washing the surface, and eluting the materials from the material-ligand complex. The surface is operational to separate materials. The surface includes a ligand operable to associate with the materials. The ligand includes a hydrophobic unit and an anionic unit.